All evidence | Drugs and Technologies | Medicines Current Awareness | National Institute for Health and Care Excellence - NICE, British National Formulary for Children - BNFc, Royal College of Psychiatrists - RCPsych, Brain Tumour Charity, Arthritis Research UK, Canadian Paediatric Society, British HIV Association - BHIVA, European Society of Gastrointestinal Endoscopy, Royal College of Obstetricians and Gynaecologists - RCOG, European Centre for Disease Prevention and Control | Search results page 1 | Evidence search

Add this result to my export selection

Baricitinib for treating moderate to severe atopic dermatitis - guidance (TA681)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

03 March 2021

Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma - guidance (TA680)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

03 March 2021

Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - guidance (TA684)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

17 March 2021

Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor - guidance (TA670)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

27 January 2021

Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies - guidance (TA669)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

27 January 2021

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adult

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Brolucizumab for treating wet age-related macular degeneration - guidance (TA672)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

03 February 2021

Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Mepolizumab for treating severe eosinophilic asthma - guidance (TA671)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

03 February 2021

Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Erenumab for preventing migraine - guidance (TA682)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

10 March 2021

Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - guidance (TA687)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

31 March 2021

Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)
Add this result to my export selection

Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) - guidance (TA686)

Source:

National Institute for Health and Care Excellence - NICE (Remove filter)

31 March 2021

NICE is unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in

Read Summary

Type:

Guidance (Add filter)

Type:

Medicines Current Awareness (Remove filter)

Search results

Filter

Evidence type

Area of interest

Source

Filter by Date

Accredited

99 results for All evidence

Baricitinib for treating moderate to severe atopic dermatitis - guidance (TA681)

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma - guidance (TA680)

Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease - guidance (TA684)

Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor - guidance (TA670)

Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies - guidance (TA669)

Brolucizumab for treating wet age-related macular degeneration - guidance (TA672)

Mepolizumab for treating severe eosinophilic asthma - guidance (TA671)

Erenumab for preventing migraine - guidance (TA682)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - guidance (TA687)

Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) - guidance (TA686)